Transitional Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Transitional Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-07-21EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small ce…
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
-
EMA approval · 2026-04-28EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.
-
EMA approval · 2026-03-30EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
The European Medicines Agency authorized Tecentriq (atezolizumab) by Roche Registration GmbH for multiple cancer indications, including non-…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-07-16EMA Authorised: Javlor (vinflunine) — Pierre Fabre Medicament
The European Medicines Agency authorised Javlor (vinflunine) from Pierre Fabre Medicament for transitional cell carcinoma of the urothelium …